NUWE Nuwellis, Inc.

Nasdaq Electromedical & Electrotherapeutic Apparatus DE CIK: 0001506492
AI RATING
STRONG_SELL
95% Confidence

Investment Thesis

Nuwellis exhibits severe financial distress with persistent operating losses, negative margins across all profitability metrics, and deteriorating cash burn. The company is losing $2.11 on every dollar of revenue while burning through ~$10.9M in free cash flow annually, creating an unsustainable business model with limited runway given only $1.1M in cash reserves.

Strengths

  • + Gross margin of 62% demonstrates viable underlying product economics
  • + Current ratio of 1.71x provides near-term liquidity cushion
  • + Debt-to-equity of 0.75x is relatively moderate compared to profitability crisis

Risks

  • ! Operating losses of -$11.1M dwarf $8.3M revenue, indicating fundamental business model failure
  • ! Negative free cash flow of -$10.9M with only $1.1M cash creates acute solvency risk
  • ! ROE of -667.7% and ROA of -286.4% indicate shareholder capital is being destroyed at accelerating rates
  • ! Interest coverage of -22.0x shows inability to service debt from operations
  • ! Revenue declining 5.4% YoY while losses expand, indicating market rejection and scaling problems

Key Metrics to Watch

Financial Metrics

Revenue
8.3M
Net Income
-17.5M
EPS (Diluted)
$-25.39
Free Cash Flow
-10.9M
Total Assets
6.1M
Cash
1.1M

Profitability Ratios

Gross Margin 62.0%
Operating Margin -134.3%
Net Margin -211.9%
ROE -667.7%
ROA -286.4%
FCF Margin -131.8%

Balance Sheet & Liquidity

Current Ratio
1.71x
Quick Ratio
1.08x
Debt/Equity
0.75x
Debt/Assets
57.0%
Interest Coverage
-22.04x
Long-term Debt
2.0M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-04-03T22:52:11.347415 | Data as of: 2025-12-31 | Powered by Claude AI